These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9591707)

  • 1. Concerning the anti-major histocompatibility complex approach to HIV type 1 vaccine design.
    Luscher MA; Dela Cruz CS; MacDonald KS; Barber BH
    AIDS Res Hum Retroviruses; 1998 May; 14(7):541-4. PubMed ID: 9591707
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospects for vaccine protection against HIV-1 infection and AIDS.
    Letvin NL; Barouch DH; Montefiori DC
    Annu Rev Immunol; 2002; 20():73-99. PubMed ID: 11861598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AIDS vaccine development in primate models.
    Almond NM; Heeney JL
    AIDS; 1998; 12 Suppl A():S133-40. PubMed ID: 9632994
    [No Abstract]   [Full Text] [Related]  

  • 4. HIV type 1 vaccine-induced cytotoxic T cell responses: potential role in vaccine efficacy.
    Ada GL; McElrath MJ
    AIDS Res Hum Retroviruses; 1997 Feb; 13(3):205-10. PubMed ID: 9115805
    [No Abstract]   [Full Text] [Related]  

  • 5. HIV/AIDS vaccines: 2007.
    Robinson HL
    Clin Pharmacol Ther; 2007 Dec; 82(6):686-93. PubMed ID: 17971817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
    Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
    J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CTL ontogeny and viral escape: implications for HIV-1 vaccine design.
    Yang OO
    Trends Immunol; 2004 Mar; 25(3):138-42. PubMed ID: 15036041
    [No Abstract]   [Full Text] [Related]  

  • 8. Primate models of AIDS vaccine development.
    Lamb-Wharton RJ; Joag SV; Stephens EB; Narayan O
    AIDS; 1997; 11 Suppl A():S121-6. PubMed ID: 9451975
    [No Abstract]   [Full Text] [Related]  

  • 9. Protection against human immunodeficiency virus type 2 and simian immunodeficiency virus in macaques vaccinated against human immunodeficiency virus type 2.
    Biberfeld G; Thorstensson R; Putkonen P
    AIDS Res Hum Retroviruses; 1996 Mar; 12(5):443-6. PubMed ID: 8882330
    [No Abstract]   [Full Text] [Related]  

  • 10. Building on the past to define an efficient path to an HIV vaccine.
    Korber B
    Expert Rev Vaccines; 2011 Jul; 10(7):929-31. PubMed ID: 21806390
    [No Abstract]   [Full Text] [Related]  

  • 11. Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus.
    Cranage MP; Polyanskaya N; McBride B; Cook N; Ashworth LA; Dennis M; Baskerville A; Greenaway PJ; Corcoran T; Kitchin P
    AIDS Res Hum Retroviruses; 1993 Jan; 9(1):13-22. PubMed ID: 8427714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of a vaccine against HIV: is this aim accomplishable?].
    Wagner R; Asbach B
    MMW Fortschr Med; 2013 Jun; 155 Suppl 1():36-9. PubMed ID: 23961653
    [No Abstract]   [Full Text] [Related]  

  • 13. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection.
    Liu Q; Li Y; Luo Z; Yang G; Liu Y; Liu Y; Sun M; Dai J; Li Q; Qin C; Shao Y
    AIDS; 2015 Mar; 29(6):649-58. PubMed ID: 25849828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
    Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aiming for successful vaccine-induced HIV-1-specific cytotoxic T lymphocytes.
    Yang OO
    AIDS; 2008 Jan; 22(3):325-31. PubMed ID: 18195558
    [No Abstract]   [Full Text] [Related]  

  • 17. Humoral immunity to HIV, SIV, and SHIV.
    Haigwood NL; Zolla-Pazner S
    AIDS; 1998; 12 Suppl A():S121-32. PubMed ID: 9632993
    [No Abstract]   [Full Text] [Related]  

  • 18. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
    Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
    AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccines and immunology: elucidating immunity to HIV-1 and current prospects for AIDS vaccine development.
    Heeney JL; Hahn BH
    AIDS; 2000; 14 Suppl 3():S125-7. PubMed ID: 11086855
    [No Abstract]   [Full Text] [Related]  

  • 20. AIDS vaccine development and challenge viruses: getting real.
    Vlasak J; Ruprecht RM
    AIDS; 2006 Nov; 20(17):2135-40. PubMed ID: 17086052
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.